Surrozen receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Surrozen Inc (SRZN)
Track the Surrozen share price today and view real-time SRZN share price data, including charts, technicals, and key financials. View the SRZN premarket stock price ahead of the market session or assess the after hours quote. Explore SRZN stock price movements, trading volume, and market activity across the NASDAQ exchange.
What Is the Surrozen Stock Price Today?
The Surrozen stock price today is 30.750.
What Is the Stock Symbol for Surrozen?
The stock symbol for Surrozen is ""SRZN.""
What Stock Exchange Does Surrozen Trade On?
Surrozen is listed and trades on the NASDAQ stock exchange.
Is Surrozen a Good Stock to Buy?
Determining whether Surrozen or any stock is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the SRZN quote. (ISIN: US86889P2083)
What Is the Surrozen Stock Price Today?
The Surrozen stock price today is 30.750.
What Is the Stock Symbol for Surrozen?
The stock symbol for Surrozen is ""SRZN.""
What Stock Exchange Does Surrozen Trade On?
Surrozen is listed and trades on the NASDAQ stock exchange.
Is Surrozen a Good Stock to Buy?
Determining whether Surrozen or any stock is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the SRZN quote. (ISIN: US86889P2083)
NASDAQ
Currency in USD
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
30.505
35.000
52 wk Range
5.900
35.000
Trading near 52-week High
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
30.50535.000
52 wk Range
5.90035.000
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
SRZN Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Analysts Sentiment
Strong Buy
Price Target
38.750
Upside
+26.02%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
2 analysts have revised their earnings upwards for the upcoming period
- Form DEF 14A Surrozen Inc For: 17 April
- Investing.com
- Surrozen’s exec. VP Li Yang sells $52,799 in shares
- Investing.com
- Form DEF 14A Surrozen For: 1 April
- Investing.com
- Surrozen receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Surrozen’s exec. VP Li Yang sells $52,799 in shares
- Investing.com
- Form 13G Surrozen For: 23 April
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Analyst Ratings
5 Buy
0 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 38.750
(+26.02% Upside)
Earnings
Latest Release
23/03/2026
EPS / Forecast
-20.09 / -1.03
Revenue / Forecast
528K / --
Compare SRZN to Peers and Sector
Metrics to compare | SRZN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipSRZNPeersSector | |
|---|---|---|---|---|
P/E Ratio | −1.5x | −96.2x | −0.5x | |
PEG Ratio | 0.03 | −1.09 | 0.00 | |
Price/Book | −1.9x | 9.0x | 2.6x | |
Price / LTM Sales | 102.4x | 9.7x | 3.2x | |
Upside (Analyst Target) | 12.8% | 120.9% | 48.3% | |
Fair Value Upside | Unlock | 29.0% | 5.6% | Unlock |
Surrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the eye, intestine, liver, lung, retina, kidney, cochlea, cornea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular age-related macular degeneration (wet AMD), and retinopathy indications; SZN-8143, which combines Fzd4 agonism, VEGF antagonism, and interleukin-6, or IL-6 for the treatment of DME/wet AMD/uveitic macular edema; and SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has a collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies; and a research collaboration agreement with TCGFB, Inc. to discover antibody therapeutics targeting transforming growth factor beta, or TGF-ß, for the treatment of patients with idiopathic pulmonary fibrosis. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Surrozen (SRZN) Stock Price Today?
The Surrozen stock price today is 30.750 USD.
What Stock Exchange Does Surrozen Trade On?
Surrozen is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Surrozen?
The stock symbol for Surrozen is "SRZN."
What Is the Surrozen Market Cap?
As of today, Surrozen market cap is 392.040M USD.
What Is Surrozen's Earnings Per Share (TTM)?
The Surrozen EPS (TTM) is -32.365.
From a Technical Analysis Perspective, Is SRZN a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
How Many Times Has Surrozen Stock Split?
Surrozen has split 1 times.
How Many Employees Does Surrozen Have?
Surrozen has 44 employees.
What is the current trading status of Surrozen (SRZN)?
As of 07/05/2026, Surrozen (SRZN) is trading at a price of 30.750 USD, with a previous close of 34.130 USD. The stock has fluctuated within a day range of 30.505 USD to 35.000 USD, while its 52-week range spans from 5.900 USD to 35.000 USD.
What Is Surrozen (SRZN) Price Target According to Analysts?
The average 12-month price target for Surrozen is 38.750 USD, with a high estimate of 42 USD and a low estimate of 36 USD. 5 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +26.02% Upside potential.
What Is the SRZN Premarket Price?
SRZN's last pre-market stock price is 34.900 USD. The pre-market share volume is 150.000, and the stock has decreased by 0.770, or 2.260%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.